Article in Advances in respiratory medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 3 institutions in 2 countries.
Hellen Cris Araújo SouzaMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.
Maycon Douglas Araújo SouzaMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.
Cássio Silva SousaMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.ORCID 0000-0002-8424-8948
Edilanne Katrine Amparo VianaMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.
Sabrina Kelly Silva AlvesMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.
Alex Oliveira MarquesMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.
Arthur Serejo Neves RibeiroMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.
Vanessa de Sousa do ValeMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.ORCID 0000-0002-6092-6257
Muhammad Torequl IslamDepartment of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh.ORCID 0000-0003-0034-8202
João Antônio Leal de MirandaDepartment of Medicine, Senador Helvidio Nunes de Barros Center, Federal University of Piauí (UFPI), Picos 64607-670, PI, Brazil.ORCID 0000-0002-0273-4169
Marcelo da Costa MotaMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.
Jefferson Almeida RochaMedicinal Chemistry and Biotechnology Research Group-QUIMEBIO, São Bernardo Science Center, Federal University of Maranhão UFMA, São Bernardo 65080-805, MA, Brazil.ORCID 0000-0001-6619-2293
Universidade Federal do Maranhão · BRGopalganj Science and Technology University · BDUniversidade Federal do Piauí · BR
Funding
Federal University of Maranhão S/NFundação de Amparo à Pesquisa e ao Desenvolvimento Científico e Tecnológico do Maranhão UNIVERSAL-06509/22
6 · The paper itself
Abstract
The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2019) etiological agent, which has a high contagiousness and is to blame for the outbreak of acute viral pneumonia, is the cause of the respiratory disease COVID-19. The use of natural products grew as an alternative treatment for various diseases due to the abundance of organic molecules with pharmacological properties. Many pharmaceutical studies have focused on investigating compounds with therapeutic potential. Therefore, this study aimed to identify potential antiviral compounds from a popular medicinal plant called
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Molecular Docking and ADME-TOX Profiling of · full record | OpenQuestion